Search
News & Events
Directing immune development to curb sky-rocketing diseaseOnce upon a time it was infectious diseases like polio, measles or tuberculosis that most worried parents. With these threats now largely under control, parents face a new challenge – sky-rocketing rates of non-infectious diseases such as asthma, allergies and autism.
Research
High incidence of obesity co-morbidities in young children: A cross-sectional studyThe prevalence of overweight and obesity in children is a public health problem because of future morbidity.
Research
Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucoseThe objective of this study was to determine whether real-time continuous glucose monitoring (CGM) with preset alarms at specific glucose levels would prove...
Research
Effect of short-term use of a continuous glucose monitoring system with a real-timeThe objective of this study was to examine whether setting the low glucose alarm of a Guardian® REAL-Time continuous glucose monitoring system (CGMS) to 80 mg/d
Research
Birthweight and the risk of childhood-onset type 1 diabetesWe investigated whether children who are heavier at birth have an increased risk of type 1 diabetes
Research
Hypoglycemia alarm enhancement using data fusionThe acceptance of closed-loop blood glucose (BG) control using continuous glucose monitoring systems (CGMS) is likely to improve.
Research
Management of type 2 diabetes in young adults aged 18–30 years: ADS/ADEA/APEG consensus statementType 2 diabetes in young adults (nominally, 18–30 years of age) is a more aggressive condition than that seen in older age, with a greater risk of major morbidity and early mortality. This first Australian consensus statement on the management of type 2 diabetes in young adults considers areas where existing type 2 diabetes guidance, directed mainly towards older adults, may not be appropriate or relevant for the young adult population.
Research
Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During JourneysThere is limited evidence supporting the recommendation that drivers with insulin-treated diabetes need to start journeys with glucose >90 mg/dL. Glucose levels of drivers with type 1 diabetes were monitored for 3 weeks using masked continuous glucose monitoring (CGM).
Research
Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data NetworkTim Liz Jones Davis MBBS DCH FRACP MD MBBS FRACP PhD Co-head, Diabetes and Obesity Research Theme Head, Chronic & Severe Diseases; Clinical Lead,